DNA Synthesizer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Benchtop DNA Synthesizers, Large-scale DNA Synthesizers), By End use (Hospitals & Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), By Application (Drug Discovery & Development, Genetic Engineering, Clinical Diagnostics) Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 261.21 Million
CAGR (2026-2031)	9.28%
Fastest Growing Segment	Pharmaceutical & Biotechnology Companies
Largest Market	North America
Market Size (2031)	USD 444.87 Million

Market Overview

The Global DNA Synthesizer Market will grow from USD 261.21 Million in 2025 to USD 444.87 Million by 2031 at a 9.28% CAGR. DNA synthesizers are automated platforms utilized to construct specific DNA sequences, known as oligonucleotides, via controlled chemical reactions for genomic applications. The market is primarily propelled by the burgeoning demand for synthetic genes in pharmaceutical development and the increasing application of genomic technologies in personalized medicine. This growth trajectory is underpinned by a robust clinical pipeline requiring precise genetic materials; according to the American Society of Gene & Cell Therapy, in 2024, there were more than 4,000 gene, cell, and RNA therapies in development globally.

However, a significant challenge facing the market is the technical limitation regarding the synthesis of long DNA sequences with high fidelity. The accumulation of errors in longer oligonucleotides often necessitates complex and costly post-synthesis purification processes, which can restrict throughput and increase operational expenses for research institutions and commercial manufacturers alike, potentially impeding widespread adoption in cost-sensitive sectors.

Key Market Drivers

The emergence of enzymatic DNA synthesis platforms represents a transformative shift in the market, fundamentally addressing the technical limitations of traditional chemical methods. Unlike phosphoramidite-based chemistry, which requires hazardous reagents and struggles with sequence fidelity at longer lengths, enzymatic approaches utilize template-independent polymerases to construct DNA under aqueous conditions. This innovation significantly enhances the ability to produce complex, high-purity sequences required for advanced genomic applications, thereby overcoming a major barrier to scalability. For instance, according to Ansa Biotechnologies, in October 2025, the company announced the commercial expansion of its proprietary enzymatic synthesis platform to produce DNA constructs up to 50 kb in length, a capability that far exceeds the typical constraints of legacy technologies.

Concurrently, the rapid expansion of the synthetic biology ecosystem is acting as a primary catalyst for market growth, driving sustained demand for large-scale gene synthesis. As investment flows into the sector, biopharmaceutical and industrial biotechnology companies are increasingly outsourcing the production of genetic materials to accelerate their research and development pipelines. This trend is underscored by robust funding activity; according to SynBioBeta, in May 2025, venture investment in the global synthetic biology sector reached $12.2 billion in 2024, signaling a strong recovery in capital inflows. This financial momentum is translating directly into revenue gains for key market players. According to Twist Bioscience, in August 2025, the company reported fiscal third-quarter revenue of $96.1 million, marking an 18% increase year-over-year driven by the heightened adoption of its synthetic biology product portfolio.

Download Free Sample Report

Key Market Challenges

The primary impediment obstructing the Global DNA Synthesizer Market is the technical limitation associated with synthesizing long DNA sequences with high fidelity. As oligonucleotide chain lengths increase, the accumulation of chemical errors necessitates rigorous and expensive post-synthesis purification processes. This requirement not only inflates operational costs but also severely restricts production throughput, making the generation of complex genetic materials commercially unviable for many cost-sensitive research institutions. Consequently, manufacturers face difficulties in scaling operations to meet the volume demands of modern genomics without incurring prohibitive expenses.

This inefficiency directly dampens market growth by widening the gap between capital influx and tangible output efficiency. The urgency for resolving this bottleneck is highlighted by the sector's significant financial footprint; according to SynBioBeta, in 2024, venture investment in the synthetic biology sector reached $12.2 billion. Despite this robust financial interest, the inability to cost-effectively produce long, error-free sequences limits the return on these investments and stalls the broader adoption of synthesizer technology in industrial-scale applications.

Key Market Trends

The adoption of decentralized benchtop DNA printing platforms is rapidly reshaping the market structure by enabling research facilities to internalize oligonucleotide production. This trend addresses the critical need for operational autonomy and faster design-build-test cycles, allowing scientists to bypass the logistical delays and data security risks associated with centralized service providers. The momentum behind this shift is evident in the strategic financing of key ecosystem players aimed at scaling localized synthesis capabilities for rapid, on-demand workflow integration. For instance, according to Telesis Bio, in March 2025, in a press release titled 'Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology,' the company secured up to $21 million in financing to drive the commercial expansion of its on-site synthesis solutions and benchtop platforms.

Simultaneously, the commercialization of DNA data storage solutions is creating a novel, high-volume application vertical distinct from traditional therapeutic workflows. As the global demand for archival capacity exceeds the physical limits of silicon and magnetic tape, the industry is pivoting toward DNA as a dense, durable medium for information preservation, necessitating specialized high-throughput synthesis infrastructure. This emerging sector is attracting significant capital to develop the dedicated writing technologies required for exabyte-scale storage systems. According to Twist Bioscience, in May 2025, in its 'Fiscal Second Quarter 2025 Financial Results,' the company announced the spin-out of Atlas Data Storage, which successfully raised $155 million in seed funding to industrialize DNA-based archival technologies and accelerate market deployment.

Segmental Insights

The Pharmaceutical and Biotechnology Companies segment is projected to be the fastest-growing category in the Global DNA Synthesizer Market due to rising investments in drug discovery and personalized medicine. These organizations are increasingly utilizing DNA synthesis to develop gene therapies and vaccines, necessitating reliable production methods for clinical research. This growth is reinforced by supportive guidelines from regulatory bodies like the U.S. Food and Drug Administration, which streamline the approval process for biologic treatments. As a result, the continuous focus on developing targeted medical solutions fuels the demand for synthesis equipment within this industry.

Regional Insights

North America maintains a dominant position in the global DNA synthesizer market, primarily driven by extensive investments in pharmaceutical and biotechnology research. The region benefits from established infrastructure that supports genomic studies and drug discovery initiatives. A significant factor contributing to this leadership is the substantial funding provided by government organizations, such as the National Institutes of Health, which facilitates continuous development in genetic analysis. Furthermore, the strong presence of key market players and the rising demand for personalized medicine in the United States secure the region's status as a primary hub for market expansion.

Recent Developments

• In January 2025, DNA Script announced a major advancement in its enzymatic synthesis technology by launching a new product capable of producing custom DNA sequences up to 500 nucleotides long. This offering overcomes previous length limitations associated with enzymatic methods and supports the generation of highly complex sequences, including those with high GC content and difficult secondary structures. The CEO of DNA Script stated that this breakthrough enables the programmable synthesis of genetic material essential for mRNA vaccine development and antibody engineering. This launch positions the company to better serve the growing demand for rapid, on-demand nucleic acid production in life sciences research.
• In August 2024, Twist Bioscience Corporation expanded its synthetic DNA product portfolio with the commercial launch of Gene Fragments ranging up to 5.0 kilobases in length. This development allows researchers to acquire longer, double-stranded DNA constructs directly, eliminating the need to stitch together shorter fragments for complex applications. The enhanced offering leverages the company's silicon-based synthesis platform to maintain high accuracy and rapid turnaround times while delivering extended sequence lengths. By providing these larger genetic payloads, Twist Bioscience aims to support a broader range of scientific workflows, including the development of RNA therapeutics and advanced protein engineering.
• In June 2024, GenScript Biotech Corporation launched its FLASH Gene service, a new offering designed to provide ultra-fast gene synthesis solutions to the global life sciences market. This service guarantees the delivery of plasmid constructs from sequences in as few as four business days, addressing the industry's critical need for speed and efficiency in research and development. The proprietary technology ensures high-yield and complete sequence accuracy, facilitating rapid iterations for researchers working on antibody drugs, vaccines, and cell therapies. The launch represents a significant enhancement to the company's semiconductor-based synthesis platform, aiming to drastically reduce turnaround times for complex genetic projects.
• In January 2024, Elegen announced a strategic collaboration and licensing agreement with GSK to integrate its proprietary cell-free DNA manufacturing technology into the pharmaceutical company's vaccine and medicine development pipelines. Under the terms of this multi-year agreement, the company is eligible to receive up to $35 million in near-term financial support and fees, in addition to potential revenues from the purchase of its synthetic DNA products. This partnership aims to leverage Elegen’s rapid production capabilities to accelerate the discovery and clinical scale-up of genetic medicines, including mRNA, cell, and viral gene therapies, thereby streamlining the transition from laboratory research to clinical manufacturing.

Key Market Players

• Danaher Corporation
• Twist Bioscience Corporation
• LGC Limited
• CSBio Co.
• K&A Labs GmbH
• DNA Script SAS
• OligoMaker ApS
• PolyGen GmbH
• Biolytic Lab Performance Inc.

By Type	By End use	By Application	By Region
Benchtop DNA Synthesizers Large-scale DNA Synthesizers	Hospitals & Clinical Laboratories Academic & Research Institutes Pharmaceutical & Biotechnology Companies	Drug Discovery & Development Genetic Engineering Clinical Diagnostics	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global DNA Synthesizer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• DNA Synthesizer Market, By Type:

• Benchtop DNA Synthesizers
• Large-scale DNA Synthesizers

• DNA Synthesizer Market, By End use:

• Hospitals & Clinical Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies

• DNA Synthesizer Market, By Application:

• Drug Discovery & Development
• Genetic Engineering
• Clinical Diagnostics

• DNA Synthesizer Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE